Effects of steroid 5α-reductase inhibitor ONO-9302 and anti-androgen allylestrenol on the prostatic growth, and plasma and prostatic hormone levels in rats

Japanese Journal of Pharmacology

Volumn 74, Issue 3, 1997, Pages 243-252

  Yasuda, Naohiro ^a   Fujino, Katsuhiro ^a   Shiraji, Takamitsu ^a   Nambu, Fumio ^a   Kondo, Kigen ^a  

^a ONO PHARMACEUTICAL CO   (Japan)

Author keywords

Dihydrotestosterone; ONO 9302; Prostate; Steroid 5 reductase; Testosterone

Indexed keywords

ALLYLESTRENOL; ANDROSTANOLONE; EPRISTERIDE; FOLLITROPIN; LUTEINIZING HORMONE; PERSELIN; STEROID 5ALPHA REDUCTASE INHIBITOR; TESTOSTERONE; TESTOSTERONE PROPIONATE; UNCLASSIFIED DRUG; ANDROGEN RECEPTOR; ANDROSTANE DERIVATIVE; ENZYME INHIBITOR; PROGESTERONE DERIVATIVE; STEROID 5ALPHA REDUCTASE;

ADRENAL GLAND; ANIMAL EXPERIMENT; ARTICLE; BODY WEIGHT; CASTRATION; CONTROLLED STUDY; DRUG POTENCY; EPIDIDYMIS; FOLLITROPIN BLOOD LEVEL; HORMONE BLOOD LEVEL; KIDNEY MASS; LIVER WEIGHT; LUTEINIZING HORMONE BLOOD LEVEL; MALE; NONHUMAN; ORAL DRUG ADMINISTRATION; ORGAN WEIGHT; PROSTATE; RAT; TESTIS WEIGHT; TESTOSTERONE BLOOD LEVEL; ANIMAL; BLOOD; COMPARATIVE STUDY; DRUG ANTAGONISM; DRUG EFFECT; GROWTH, DEVELOPMENT AND AGING; HISTOLOGY; METABOLISM; ORGAN SIZE; SPRAGUE DAWLEY RAT; TESTIS;

ALLYLESTRENOL; ANDROSTADIENES; ANIMALS; ENZYME INHIBITORS; FOLLICLE STIMULATING HORMONE; LUTEINIZING HORMONE; MALE; ORGAN SIZE; PROGESTERONE CONGENERS; PROSTATE; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, ANDROGEN; TESTIS; TESTOSTERONE; TESTOSTERONE 5-ALPHA-REDUCTASE;

EID: 0030612258     PISSN: 00215198     EISSN: None     Source Type: Journal    
DOI: 10.1254/jjp.74.243     Document Type: Article

References (54)

1. Wilson JD: The pathogenesis of benign prostatic hyperplasia. Am J Med 68, 745-756 (1980)
2. Berry SJ, Coffey DS, Walsh PC and Ewing LL: The development of human benign prostatic hyperplasia with age. J Urol 132, 474-479 (1984)
3. Hicks RJ and Cook JB: Managing patients with benign prostatic hyperplasia. Am Fam Physician 52, 135-142 (1995)
4. Mooradian AD, Morley JE and Korenman SG: Biological actions of androgens. Endocr Rev 8, 1-28 (1987)
5. Donkervoort T, Zinner NR, Sterling AM, Donker PJ, Van Ness J and Ritter RC: Megestrol acetate in treatment of benign prostatic hypertrophy. Urology 6, 580-587 (1975)
6. Scott WW and Wade JC: Medical treatment of benign nodular prostatic hyperplasia with cyproterone acetate. J Urol 101, 81-85 (1969)
7. Yamanaka H, Kosaku N, Makino T and Shida K: Fundamental and clinical study of the anti-prostatic effect of allylestrenol. Hinyokika Kiyo 29, 1133-1145 (1983) (Abstr in English)
8. Geller J: Benign prostatic hyperplasia: pathogenesis and medical therapy. J Am Geriatr Soc 39, 1208-1216 (1991)
9. Umeda K: Clinical results and problems of anti-androgen therapy of benign prostatic hypertrophy. Hinyokika Kiyo 37, 1429-1433 (1991) (Abstr in English)
10. McConnell JD: Androgen ablation and blockade in the treatment of benign prostatic hyperplasia. Urol Clin North Am 17, 661-670 (1990)
11. Kumamoto Y, Yamaguchi Y and Sato Y: Effects of anti-androgens on sexual function. Double-blind comparative studies on allylestrenol and chlormadinone acetate Part I: Nocturnal penile tumescence monitoring. Hinyokika Kiyo 36, 213-226 (1990) (Abstr in English)
12. Csaba G, Karabelyos C and Dallo J: Fetal and neonatal action of a polycyclic hydrocarbon (benzpyrene) or a synthetic steroid hormone (allylestrenol) as reflected by the sexual behaviour of adult rats. J Dev Physiol 19, 67-70 (1993)
13. Imperato-McGinley J, Guerrero L, Gautier T and Peterson RE: Steroid 5α-reductase deficiency in man: an inherited form of male pseudohermaphroditism. Science 186, 1213-1215 (1974)
14. Peterson RE, Imperato-McGinley J, Gautier T and Sturla E: Male pseudohermaphroditism due to steroid 5α-reductase deficiency. Am J Med 62, 170-191 (1977)
15. Imperato-McGinley J, Peterson RE, Gautier T and Sturla E: Male pseudohermaphroditism secondary to 5α-reductase deficiency - a model for the role of androgens in both the development of the male phenotype and the evolution of a male gender identity. J Steroid Biochem 11, 637-645 (1979)
16. Bruchovsky N and Wilson JD: The intranuclear binding of testosterone and 5α-androstan-17-beta-ol-3-one by rat prostate. J Biol Chem 243, 5953-5960 (1968)
17. Fang S and Liao S: Androgen receptors. Steroid- and tissue-specific retention of a 17 beta-hydroxy-5α-androstan-3-one-protein complex by the cell nuclei of ventral prostate. J Biol Chem 246, 16-24 (1971)
18. Bruchovsky N: Comparison of the metabolites formed in rat prostate following the in vivo administration of seven natural androgens. Endocrinology 89, 1212-1222 (1971)
19. Krieg M, Bartsch W, Janssen W and Voigt KD: A comparative study of binding, metabolism and endogenous levels of androgens in normal, hyperplastic and carcinomatous human prostate. J Steroid Biochem 11, 615-624 (1979)
20. Klein H, Bressel M, Kastendieck H and Voigt KD: Quantitative assessment of endogenous testicular and adrenal sex steroids and of steroid metabolizing enzymes in untreated human prostatic cancerous tissue. J Steroid Biochem 30, 119-130 (1988)
21. Anderson KM and Liao S: Selective retention of dihydrotestosterone by prostatic nuclei. Nature 219, 277-279 (1968)
22. Wilbert DM, Griffin JE and Wilson JD: Characterization of the cytosol androgen receptor of the human prostate. J Clin Endocrinol Metab 56, 113-120 (1983)
23. Coffey DS and Pienta KJ: New concepts in studying the control of normal and cancer growth of the prostate. Rev Prog Clin Biol Res 239, 1-73 (1987)
24. Allan GF, Tsai SY, O'Malley BW and Tsai MJ: Steroid hormone receptors and in vitro transcription. Bioessays 13, 73-78 (1991)
25. O'Malley BW, Tsai SY, Bagchi M, Weigel NL, Schrader WT and Tsai MJ: Molecular mechanism of action of a steroid hormone receptor. Recent Prog Horm Res 47, 1-24 (1991)
26. Bruchovsky N and Wilson JD: The conversion of testosterone to 5α-androstan-17-beta-ol-3-one by rat prostate in vivo and in vitro. J Biol Chem 243, 2012-2021 (1968)
27. Metcalf BW, Levy MA and Holt DA: Inhibitors of steroid 5α-reductase in benign prostatic hyperplasia, male pattern baldness and acne. Trends Pharmacol Sci 10, 491-495 (1989)
28. Levy MA, Brandt M, Holt DA and Metcalf BW: Interaction between rat prostatic steroid 5α-reductase and 3-carboxy-17 beta-substituted steroids: novel mechanism of enzyme inhibition. J Steroid Biochem 34, 571-575 (1989)
29. Holt DA, Levy MA, Oh HJ, Erb JM, Heaslip JI, Brandt M, Lan-Hargest HY and Metcalf BW: Inhibition of steroid 5α-reductase by unsaturated 3-carboxysteroids. J Med Chem 33, 943-950 (1990)
30. Levy MA, Metcalf BW, Brandt M, Erb JM, Oh HJ, Heaslip JI, Yen HK, Rozamus LW and Holt DA: 3-Phosphinic acid and 3-phosphonic acid steroids as inhibitors of steroid 5α-reductase: species comparison and mechanistic studies. Bioorg Chem 19, 245-260 (1991)
31. Liang T, Cascieri MA, Cheung AH, Reynolds GF and Rasmusson GH: Species differences in prostatic steroid 5α-reductases of rat, dog, and human. Endocrinology 117, 571-579 (1985)
32. Amemiya Y and Miyahara J: Imaging plate illuminates many fields. Nature 336, 89-90 (1988)
33. 14C in microplates by radioluminography. Appl Radiat Isot 44, 1011-1014 (1993)
34. Okuyama M, Hatori Y and Shigematsu A: Autoradioluminography, a novel quantitative method of TLC-autoradiography. Biol Pharm Bull 17, 559-563 (1994)
35. 14C. Eur J Drug Metab Pharmacokinet 20, 89-105 (1995)
36. Ewing LL, Berry SJ and Higginbottom EG: Dihydrotestosterone concentration of beagle prostatic tissue: effect of age and hyperplasia. Endocrinology 113, 2004-2009 (1983)
37. Turner TT, Jones CE, Howards SS, Ewing LL, Zegeye B and Gunsalus GL: On the androgen microenvironment of maturing spermatozoa. Endocrinology 115, 1925-1932 (1984)
38. Kyprianou N and Isaacs JT: Biological significance of measurable androgen levels in the rat ventral prostate following castration. Prostate 10, 313-324 (1987)
39. Krieg M, Nass R and Tunn S: Effect of aging on endogenous level of 5α-dihydrotestosterone, testosterone, estradiol, and estrone in epithelium and stroma of normal and hyperplastic human prostate. J Clin Endocrinol Metab 77, 375-381 (1993)
40. Chen H, Chandrashekar V and Zirkin BR: Can spermatogenesis be maintained quantitatively in intact adult rats with exogenously administered dihydrotestosterone? J Androl 15, 132-138 (1994)
41. Bradford MM: A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 72, 248-254 (1976)
42. Prasad MR and Rajalakshmi M: Recent advances in the control of male reproductive functions. Int Rev Physiol 13, 153-199 (1977)
43. Calandra RS, Blaquier JA, del Castillo EJ and Rivarola MA: Androgen dependency of the androgen receptor in rat epididymis. Biochem Biophys Res Commun 67, 97-102 (1975)
44. Podesta EJ, Calandra RS, Rivarola MA and Blaquier JA: The effect of castration and testosterone replacement on specific proteins and androgen levels of the rat epididymis. Endocrinology 97, 399-405 (1975)
45. Pujol A and Bayard F: Androgen receptors in the rat epididymis and their hormonal control. J Reprod Fertil 56, 217-222 (1979)
46. de Larminat MA, Monsalve A, Charreau EH, Calandra RS and Blaquier JA: Hormonal regulation of 5α-reductase activity in rat epididymis. J Endocrinol 79, 157-165 (1978)
47. Lamb JC, English H, Levandoski PL, Rhodes GR, Johnson RK and Isaacs JT: Prostatic involution in rats induced by a novel 5α-reductase inhibitor, SK&F 105657: role for testosterone in the androgenic response. Endocrinology 130, 685-694 (1992)
48. Levy MA, Brandt M, Sheedy KM, Dinh JT, Holt DA, Garrison LM, Bergsma DJ and Metcalf BW: Epristeride is a selective and specific uncompetitive inhibitor of human steroid 5α-reductase isoform 2. J Steroid Biochem Mol Biol 48, 197-206 (1994)
49. Andersson S, Berman DM, Jenkins EP and Russell DW: Deletion of steroid 5α-reductase 2 gene in male pseudohermaphroditism. Nature 354, 159-161 (1991)
50. Andersson S, Bishop RW and Russell DW: Expression cloning and regulation of steroid 5α-reductase, an enzyme essential for male sexual differentiation. J Biol Chem 264, 16249-16255 (1989)
51. Jenkins EP, Andersson S, Imperato-McGinley J, Wilson JD and Russell DW: Genetic and pharmacological evidence for more than one human steroid 5a-reductase. J Clin Invest 89, 293-300 (1992)
52. Harris G, Azzolina B, Baginsky W, Cimis G, Rasmusson GH, Tolman RL, Raetz CR and Ellsworth K: Identification and selective inhibition of an isozyme of steroid 5α-reductase in human scalp. Proc Natl Acad Sci USA 89, 10787-10791 (1992)
53. Thigpen AE and Russell DW: Four-amino acid segment in steroid 5α-reductase 1 confers sensitivity to finasteride, a competitive inhibitor. J Biol Chem 267, 8577-8583 (1992)
54. Brooks JR, Baptista EM, Berman C, Ham EA, Hichens M, Johnston DBR, Primka RL, Rasmusson GH, Reynolds GF, Schmitt SM and Arth GE: Reponse of rat ventral prostate to a new and novel 5α-reductase inhibitor. Endocrinology 109, 830-836 (1981)